Precision Medicine News and Research

RSS

DNA analysis outperforms standard newborn screening, study shows

Early results from a study of newborn screening methods show that DNA analysis picks up many more preventable or treatable serious health conditions than standard newborn screening and is favored by most parents who are offered the option.

24 Oct 2024

ECOG-ACRIN and Caris Life Sciences launch collaborative cancer research initiative

ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences(Caris) announced today a multi-year research collaboration wherein Caris is pairing its highly sophisticated and comprehensive genomic, transcriptomic and proteomic profiling, advanced artificial intelligence (AI) and machine learning algorithms with ECOG-ACRIN's immense research capabilities.

24 Oct 2024

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

NIH launches precision medicine trial to test new treatments for myeloid cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

23 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

AI system BELA revolutionizes assessment of IVF embryos

A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.

22 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

18 Oct 2024

Major donation fuels advances in ophthalmic artificial intelligence

The Icahn School of Medicine has announced a $5 million gift from the John and Daria Barry Foundation for the Center for Ophthalmic Artificial Intelligence (AI) and Human Health.

16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

From Ubiquigent Limited 16 Oct 2024

Differential gene expression linked to alcohol use disorder, offering new treatment possibilities

Researchers identified key gene expression differences in addiction-relevant brain regions that provide new insights into alcohol use disorder and potential therapeutic targets.

14 Oct 2024

University of Michigan receives $30 million grant to enhance genetic data storage

The University of Michigan will dramatically boost the amount and type of genetic information stored in its massive TOPMed data center and used by researchers and healthcare providers around the world looking to genomes to treat disease.

14 Oct 2024

Boost your heart, save your brain: How better heart health fights dementia

Research highlights the strong connection between heart and brain health, showing that improving cardiovascular health can help prevent cognitive decline and dementia. It underscores the shared biological mechanisms that link cardiac diseases to neurological impairment.

13 Oct 2024

UCLA study reveals key signs for genetic testing in neurodevelopment disorders

In a new study, UCLA Health researchers have found that motor delay and low muscle tone were common signs of an underlying genetic diagnosis in children with neurodevelopment disorders.

12 Oct 2024

Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).

10 Oct 2024

Study illuminates the origin and progression of bladder cancer

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center.

9 Oct 2024

Liver cancer patients gain clarity on surgery options through precision medicine tool

Duke-NUS alumnus Dr Marjorie Hoang (Class of 2023) and her mentor, Professor Pierce Chow, have brought clarity to the complex decision-making process patients diagnosed with intermediate-stage liver cancer and their doctors face by creating an algorithm that can accurately calculate the likely overall survival and recurrence-free survival following surgery.

9 Oct 2024

Deciphering the Mysteries of the Human Microbiome

The Microsetta Initiative studies human microbiomes, analyzing diverse data to reveal links between microbes, diet, and health for improved public health.

8 Oct 2024

AI and imaging tools to drive personalized cancer treatments in Europe

Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies ("Theranostics") to target cancer first at the "diagnosis" phase and then at the "therapy" phase, using the same biological targets ("see to treat").

8 Oct 2024

Owkin partners with AstraZeneca to enhance gBRCA testing for breast cancer

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

4 Oct 2024